Across the globe, pharma companies are experiencing new levels of price resistance and competitive pressure. No one wants to spend more than they already do – unless they’re given a compelling reason. The only counter to that pressure is compelling evidence of differentiated value. Once considered nice-to-have, real-world evidence (RWE) has become a critical success factor.

At the same time, new regulatory measures like the IRA in the U.S. have forced reduced revenue projections and widespread budget cuts. Unfortunately, just as evidentiary standards for pricing and access are increasing, many companies have reduced or eliminated needed resources. As budgets become tighter, organizations will need to approach evidence generation in a way that ensures the right evidence is developed while optimizing the resource spend.